pembrolizumab
merck
['melsm', 'pembro', 'melanoma']
distant metastasis-free and recurrence-free survival were better in patients with resected stage ii melanoma who were treated with adjuvant pembrolizumab vs placebo. #melsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.